News

 

 

Recently Opened Clinical Trials

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy
Novartis Pharmaceuticals
A Phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy
Bristol Myers Squibb
Phase 2, randomized, double-blinded, study of nivolumab (BMS-936558) in combination with ipilimumab vs ipilimumab alone in subjects with previously untreated, unresectable or metastatic melanoma

Gary Schwartz
Associate Professor
Molecular Therapeutics
SWOG
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer. e3 breast cancer study- evaluating everolimus with endocrine therapy